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Abstract
We have developed a highly effective method for in vivo gene silencing in the spinal cord and dorsal
root ganglia (DRG) by a cationic lipid facilitated delivery of synthetic, small interfering RNA
(siRNA). A siRNA to the delta opioid receptor (DOR), or a mismatch RNA, was mixed with the
transfection reagent, i-Fect™ (vehicle), and delivered as repeated daily bolus doses (0.5 µg to 4 µg)
via implanted intrathecal catheter to the lumbar spinal cord of rats. Twenty-four hours after the
last injection, rats were tested for antinociception by the DOR selective agonist, [D-Ala2,
Glu4]deltorphin II (DELT), or the mu opioid receptor (MOR) selective agonist, [D-Ala2, N-Me-
Phe4, Gly-ol5]enkephalin (DAMGO). Pretreatment with the siRNA, but not the mismatch RNA or
vehicle alone, blocked DELT antinociception dose-dependently. The latter was concomitant with a
reduction in the spinal immunoreactivity and receptor density of DOR, and in DOR transcripts in
the lumbar DRG and spinal dorsal horn. Neither siRNA nor mismatch RNA pretreatment altered
spinal immunoreactivity of MOR or antinociception by spinal DAMGO, and had no effect on the
baseline thermal nociceptive threshold. The inhibition of function and expression of DOR by siRNA
was reversed by 72 hr after the last RNA injection. The uptake of fluorescence-tagged siRNA was
detected in both DRG and spinal cord. The low effective dose of siRNA/i-Fect™ complex reflects
an efficient delivery of the siRNA to peripheral and spinal neurons, produced no behavioral signs
of toxicity. This delivery method may be optimized for other gene targets.
Background
RNA interference (RNAi) is an endogenous mechanism of
RNA dependent degradation of specific mRNA by a pro-
tein complex called the RNA induced silencing complex
(RISC) [1]. This mechanism was first characterized in the
nematode Caenorhabditis elegans as an intrinsic protective
response against invaded viral RNA [2]. The sequence spe-
cific substrate selectivity of RISC is dictated by its complex
formation with certain double stranded, small interfering
RNA (siRNA) that, in the nematode, is generated from
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sequently, it was demonstrated that RNAi could be
achieved in cultured mammalian cells by transfecting
them with chemically synthesized siRNA [4], or by plas-
mid generated siRNA [5], thus establishing a new technol-
ogy for functional genomics as well as drug target
validation. In vertebrate experimental models, RNAi has
been successfully applied to target exogenous and endog-
enous gene expression in organ systems such as liver,
spleen, kidney, lung, and pancreas via systemic delivery
[6-10]. However, this novel technology is not readily ame-
nable to targeting nervous system genes because siRNA
does not easily cross the blood brain barrier, and its
uptake by neurons in vitro is poor [11]. While chemical
modification of siRNA may enhance the efficiency of
uptake of these molecules in cultured neurons as demon-
strated recently [12], only a few studies to date succeeded
in knocking down target genes in the central nervous sys-
tem (CNS) [13-16]. We proposed that the limited advance
made in the latter could be improved by establishing a
paradigm that efficiently delivers the siRNA to the CNS
and can be optimized for a variety of targets.
We have previously shown that the delta opioid receptor
(DOR) can be effectively knocked down in vitro [17] and
in vivo [18,19] by antisense oligodeoxynucleotide (ODN)
treatment. In vivo, an antisense ODN to the DOR, at a dose
of 12.5 µg (1.6 nmol), given twice daily, produced a
robust inhibition, by day 3, of antinociception of the
DOR selective agonist, [D-Ala2, Glu4]deltorphin II (DELT)
when given intracerebroventricularly [18] or intrathecally
[19]. We thus postulate that the DOR is a suitable proto-
typic nervous system gene target for the purpose of opti-
mizing in vivo RNAi by siRNA based on our prior
experience with delivery and dosing of ODN, time course
of the knockdown and turnover rate of the DOR. Another
critical advantage is the well-established protocols and
reagents for measuring the expression and function of
DOR. We show here that a low dose of 2 µg of siRNA
when mixed with a transfection agent, i-Fect™, and given
once daily by the intrathecal route, effectively abolishes
the function of DOR in the lumbar spinal cord. A selective
reduction in the transcript and protein level of DOR in the
lumbar dorsal root ganglia (DRG) and in the lumbar dor-
sal horn of the spinal cord suggests that the inhibitory
effect of the siRNA on DOR is specific to its knockdown of
DOR expression. The uptake of the siRNA by cells in the
DRG and the spinal cord is consistent with its site of
action. The effect of the siRNA is abolished by scrambling
its sequence, or by discontinuing the siRNA treatment.
The effective dose of the siRNA requires the use of i-Fect™,
which facilitates the uptake of the siRNA into target
tissues.
Results
Intrathecal administration of a siRNA to DOR blocked 
spinal DELT antinociception
The siRNA that was designed was first evaluated for its
effect on DOR expression in vitro. This was accomplished
by transfecting the siRNA/i-Fect™ complexes into NG108-
15 cells that express endogenous DOR (the DOR in the
NG108-15 cells has the mouse genotype; while the siRNA
sequence was designed based on the rat DOR sequence, it
cross-reacts with the mouse sequence). Quantitative RT-
PCR analysis of total RNA extracts from these cells har-
vested 48 hr after transfection showed an 82.4 ± 9.2%
knockdown of the DOR transcripts compared with that in
control, non-transfected cells. For in vivo delivery, an ini-
tial experiment was conducted to determine the dose
response of the siRNA, or mismatch RNA on intrathecal
DELT antinociception (Fig. 1). Rats were given vehicle, the
siRNA or mismatch RNA once daily for 3 consecutive
days, and spinal DELT antinociception was measured 24
hr after the last injection. In the vehicle pretreated rats,
intrathecal DELT produced 60 ± 8% MPE, which was con-
Dose effect of intrathecal siRNA to DOR on the antinocicep-tive ffect of the delta opioid agonist [D-Ala2, Glu4]del-r phin II (DELT)Figur 1
Dose effect of intrathecal siRNA to DOR on the anti-
nociceptive effect of the delta opioid agonist [D-Ala2, 
Glu4]deltrophin II (DELT). DELT was given intrathecally 
(30 µg). The antinociceptive efficacy of DELT is defined as % 
antinociception measured 30 min after drug administration (n 
= 6 rats/group). Intrathecal DELT antinociception was signifi-
cantly blocked after 3 consecutive once daily dose of siRNA 
at a daily dose of 4 µg (2 µg b.i.d.) or 2 µg (*p < 0.05), when 
compared with that observed in the vehicle control group. 
Mismatch RNA at the same doses had no effect on DELT 
antinociception. The 2 µg daily dose of siRNA, when adminis-
tered without i-Fect™, did not block intrathecal DELT anti-
nociception. The 0.5 µg dose of the siRNA in i-Fect™ did 
not have any effect on intrathecal DELT antinociception. Sta-
tistical analysis was carried out by one-way ANOVA follow-
ing Dunnett's multiple comparisons.Page 2 of 8
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2 µg and 4 µg (as two 2 µg doses, one at 0900 and one at
1600 hr) daily dose both significantly attenuated the
antinociception of DELT when compared with DELT anti-
nociception in the vehicle control, while a 0.5 µg daily
dose had no effect. The antinociception by DELT observed
in the 2 µg and 4 µg siRNA pretreated groups were not sig-
nificantly different from each other (10 ± 8% MPE, 25 ±
5% MPE, respectively; P > 0.05). The mismatch RNA
treated groups did not differ significantly from the vehicle
control irrespective of dosage of the mismatch RNA. These
data established the 2 µg daily as the approximate mini-
mum effective dose of this siRNA. However, if this dose of
the siRNA was given without the vehicle i-Fect™, the sub-
sequent antinociceptive effect of intrathecal DELT was
robust, and was not significantly different from that
observed in the vehicle pretreated group, or mismatch
RNA treated groups (Fig. 1). Notably, none of the RNA
treatments had any effect on the baseline thermal nocice-
ptive threshold when compared with that of the vehicle
control group. The baseline thermal latencies for paw
withdrawal in the vehicle, siRNA (2 µg/day for 3 days),
and mismatch RNA groups prior to treatment were: 20 ±
1.5 sec, 21 ± 1.1 sec, and 20 ± 1.1 sec, respectively. Twenty-
four hr after the last injection, the baseline thermal laten-
cies were 20 ± 1.0 sec, 19 ± 1.5 sec, and 20 ± 1.0 sec,
respectively. Neither vehicle nor RNA treatment precipi-
tated overt signs of behavioral toxicity or motor impair-
ment in the animals. All subsequent siRNA or mismatch
RNA treatment employed the 3 consecutive daily dose of
2 µg given with i-Fect™.
The inhibitory effect of siRNA treatment on DELT 
antinociception is transient and reversible
Whereas spinal DELT antinociception was attenuated
after siRNA treatment, determined at 24 hr after the last
siRNA injection, when the animals were tested again 48 hr
later (i.e., 72 hr after the last injection), DELT antinocice-
ption was not different when compared with that in mis-
match RNA and vehicle control groups (Fig. 2).
Knockdown of DOR in the spinal dorsal horn by the siRNA
Figure 3 shows the saturation analysis of DOR in the spi-
nal dorsal horn by the selective antagonist, [3H]naltrin-
dole. SiRNA, but not mismatch RNA, produced a
significant reduction in the density of the DOR measured
as the maximum specific binding (Bmax) of the radiolig-
and when compared with that in the vehicle treated con-
trols. The reduction represents ~70% knockdown of the
DOR density after siRNA treatment. The dissociation con-
stant (Kd) for [3H]naltrindole was not different in the
three treatment groups. Immunohistochemical analysis
using an anti-DOR antibody showed a significant reduc-
tion of immunoreactivity for DOR in the superficial lam-
inae of the dorsal horn of the lumbar spinal cord from
siRNA treated rats, but not from the mismatch RNA
treated rats (Fig. 4). Lumbar spinal dorsal horn harvested
from siRNA treated rats 72 hr after the last siRNA injection
showed strong DOR immunoreactivity, which was not
different from the vehicle or from the mismatch RNA
controls. The recovery of DOR immunoreactivity by 72 hr
after the last siRNA injection is consistent with the
observed recovery of DELT antinociception in the siRNA
treated rats at this time point shown in Fig. 2.
Spinal DELT antinociception tested 72 hours after the last RNA or vehicle i jection (n = 6/group)Figure 2
Spinal DELT antinociception tested 72 hours after 
the last RNA or vehicle injection (n = 6/group). There 
is no significant difference in the % antinociception among the 
three pretreatment groups (p > 0.05).
Saturation [3H]naltrindole binding in membranes prepared from rat dorsal lumbar spinal cord (n = 3 rats/group)Figure 3
Saturation [3H]naltrindole binding in membranes 
prepared from rat dorsal lumbar spinal cord (n = 3 
rats/group). The Bmax value in the siRNA group, but not the 
mismatch RNA group, was significantly lower than that in the 
vehicle treated group. The Kd values are not significantly dif-
ferent among the 3 groups (p > 0.05). Data are representa-
tive of 3 independent experiments.Page 3 of 8
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the DRG and the spinal dorsal horn
The mRNA levels of DOR in the lumbar spinal cord and
L4/L5 DRGs were determined by quantitative RT-PCR at
24 hr after the last siRNA injection. In the siRNA treated
group, there was a 38% reduction in DOR transcripts in
the DRG (61.9 ± 5.7% of vehicle control), and 62% reduc-
tion in the lumbar spinal cord (38 ± 17.7% of vehicle con-
trol). Mismatch RNA pretreatment did not significantly
alter the DOR mRNA level in either the DRG (109 ± 2.0%
of vehicle control) or the lumbar spinal cord (90 ± 0.01%
of vehicle control).
siRNA was taken up by DRG and spinal cord cells
AlexaFluor546-tagged siRNA fluorescence was clearly
detected in both the lumbar DRG and spinal cord 24 hr
after intrathecal delivery of 2 µg of the tagged RNA (Fig.
5A, B). In the DRG, fluorescence was present in cell bodies
of various sizes. The labeling was punctate, perinuclear,
and varied in intensity among the cells (Fig. 5A). In the
spinal cord cross sections, fluorescence could be seen dis-
tributed over the entire cross sections, labeling a large
number of cells in both the dorsal and the ventral horn, as
well as the area around the central canal. Figure 5B shows
an example of a 40 × magnification of the labeled spinal
cord cells in the superficial laminae of the dorsal horn.
The fluorescence is seen in the cytoplasm of the labeled
cells, while nuclei typically appear as dark, unlabeled
areas in the center of these cells. The localization of the
fluorescence strongly suggests that the labeling is
intracellular and thus due to the uptake of the tagged
siRNA by the DRG and the spinal cord cells. Autofluores-
cence of the tissue sections was negligible under these
imaging conditions when tissue sections from vehicle-
injected rats were analyzed (Fig. 5C, D). Notably, when
fluorescence-tagged siRNA was delivered into rats without
i-Fect™, its uptake in the lumbar DRG (Fig. 5E) as well as
in the lumbar spinal cord (Fig. 5F) was extremely poor.
DOR-immunoreactivity in the dorsal horn of the spinal cord after vehicle, siRNA or mismatch (MM) RNA r atmentFigur  4
DOR-immunoreactivity in the dorsal horn of the spi-
nal cord after vehicle, siRNA or mismatch (MM) 
RNA treatment. The immunoreactivity of DOR was pre-
dominantly found in laminae I/II of the dorsal horn. The 
immunolabeling was significantly lower in tissue from siRNA 
treated rats. Tissues taken 72 hours after the last siRNA 
injection (siRNA recovery) show similar level of immunore-
activity for DOR when compared with vehicle or MM RNA 
controls. Each image is representative of multiple sections 
from 3 rats per treatment group.
AlexaFluor546-tagged siRNA uptake in lumbar DRG (A, C, E) and spinal cord (B, D, F)Figure 5
AlexaFluor546-tagged siRNA uptake in lumbar DRG 
(A, C, E) and spinal cord (B, D, F). Vehicle (10 µL) (C, 
D), siRNA with vehicle (2 µg/ 10 µL) (A, B), or siRNA with-
out vehicle (2 µg/ 10 µL of aqueous annealing buffer) (E, F) 
was given intrathecally as a single injection. Tissues were har-
vested and processed 24 hr later. Images of the DRG were 
taken using a 20× objective lens and that of the spinal cord 
taken using a 40× objective lens. In all the fluorescence 
labeled cells, the labeling was punctate and peri-nuclear, and 
labeling intensities varied among cells. In the spinal cord (B), 
labeled cells were distributed widely in both the dorsal horn 
and the ventral horn. The images in B, D, F were taken from 
laminae I/II of the dorsal horn. Scale bar for the DRG images 
shown in panel E is 50 µm; scale bar for the spinal cord 
images shown in panel F is 25 µm.Page 4 of 8
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MOR
In vehicle-pretreated rats, DAMGO (0.5 µg) produced 66
± 16% MPE, which is consistent with that previously pub-
lished [20]. Neither siRNA to DOR, nor mismatch RNA
treatment, had any effect on intrathecal DAMGO antino-
ciception when compared with the vehicle control (79 ±
11% MPE, 73 ± 10% MPE, respectively to 66 ± 16% MPE;
P > 0.05). There was also no significant difference in the
MOR immunoreactivity in the dorsal horn of the spinal
cord between siRNA, mismatch RNA, and vehicle treated
groups (Fig. 6).
Discussion
The advances made recently toward the in vivo applica-
tions of RNAi in vertebrate systems are critical towards
developing siRNA as therapeutics [21-23]. These in vivo
applications, however, do not yet apply to central nervous
system function because siRNA do not readily cross the
blood brain barrier (BBB) via systemic delivery. Because
drugs may bypass the BBB by delivering them directly into
the CSF, such delivery routes may be exploited in order to
determine whether neurons and other cells in the nervous
system may be amenable to RNAi by siRNA in vivo. Two
recent reports used intrathecal delivery to prevent
hypoxia-induced expression of brain derived neuro-
trophic factor in the spinal cord [14], or to knockdown the
expression of the purinergic receptor subtype, P2X3, in
sensory primary afferent [15]. While both studies demon-
strated that siRNA attenuated the intended gene target, the
former was a short intervention (3.5 hr) while the experi-
mental subject was under general anesthesia, whereas the
latter required very high concentration and continuous
infusion of siRNA (400 µg/day for up to 7 days) to elicit a
modest knockdown of the target. It is not clear whether
the high dose of siRNA needed to effect reflects an ineffi-
cient RNAi mechanism in neurons or whether the modu-
lation of gene function cannot be sustained over time.
Our data show that in the presence of a suitable transfec-
tion agent, the siRNA to the DOR is highly effective at a
low concentration of 2 µg, or 0.14 nmol, given once a day.
This dose is 23 times lower than the amount of antisense
ODN required to elicit a knock down of the DOR as pre-
viously published [18], and is substantially lower than the
effective dose reported for the knock down of the P2X3
receptors in the DRG [15]. The siRNA treatment delivered
without the transfection reagent was without effect, sug-
gesting that the transfection reagent significantly
enhanced the uptake of the siRNA into target cells, as ver-
ified by the detection of fluorescence uptake of spinal cord
and DRG tissues after injecting the tagged siRNA. This
observation is consistent with recent evidence that the
uptake of siRNA by neurons in culture is likely a key lim-
iting step in the siRNA mediated gene silencing [12]. The
amount of RNA delivered as a bolus dose in transfection
reagent tends to be limited by the solubility of the RNA.
The transfection reagent used in the present study was i-
Fect™, which is a cationic lipid mixture that has been opti-
mized for the delivery of short oligonucleotides in vitro
[24]. This reagent was chosen for the present study
because the RNA/lipid complexes remain in suspension at
a fairly high concentration in a volume that is suitable for
intrathecal delivery. A maximum of 2 µg of RNA can be
given in a 10 µL injection volume. Should a daily dose of
>2 µg is desired, the delivery can be adjusted by giving
multiple doses.
A significant knockdown of DOR transcripts by siRNA
treatment is consistent with the proposed mechanism of
action of RNAi [25,26]. In this regard, the knockdown of
the DOR transcripts was observed in both the dorsal horn
of the spinal cord as well as the lumbar DRG, demonstrat-
ing that the siRNA interferes with the synthesis of both the
presynaptic and the postsynaptic populations of DOR,
which is also highly consistent with the uptake pattern of
the tagged siRNA. The effects of siRNA culminate in a
significant reduction of DOR immunoreactivity and lig-
and binding capacity in the superficial laminae of the
dorsal horn of the spinal cord where the functional recep-
tors are predominantly located. The loss of functional
DOR is evident by the loss of antinociceptive activity of
the DOR selective agonist, DELT, given intrathecally.
MOR-immunoreactivity in the dorsal horn of the spinal cord after vehicle, siRNA ( o DOR) or mismatch (MM) RNA treatm ntFigur  6
MOR-immunoreactivity in the dorsal horn of the spi-
nal cord after vehicle, siRNA (to DOR) or mismatch 
(MM) RNA treatment. The MOR immunoreactivity is 
predominantly localized to laminae I/II of the dorsal horn. No 
significant difference in the immunoreactivity for MOR was 
seen among the 3 treatment groups. Tissue taken 72 hours 
after the last siRNA injection (siRNA recovery) also showed 
similar MOR immunoreactivity as the control groups. Each 
image is representative of multiple sections processed from 3 
rats used in each group. The sections used in this figure and 
those used for DOR labeling shown in Figure 4 were from 
the same animals.Page 5 of 8
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established an effective method for delivering siRNA that
interferes efficiently with the expression and function of
target genes in both the peripheral nervous system (i.e.,
sensory primary afferent) and the central nervous system
(i.e., spinal cord).
The use of a mismatch RNA confirms the specificity of the
siRNA sequence for the DOR. The siRNA treatment had
no effect on the expression or the function of the highly
homologous receptor type, MOR, further supporting the
target specificity of the siRNA employed here. Finally, the
effect of the siRNA is fully reversible; thus the observed
effects of the siRNA are specific to the use of siRNA, and
the treatment paradigm does not precipitate any long-
term effects due to toxicity such as motor impairment.
This paradigm can be easily adjusted for dosage and dura-
tion of treatment, and is based on a well-established,
relatively non-invasive method of drug delivery that has
general applications for spinal and peripheral targets. The
reagents required are minimal and economical, and can
be adapted for other gene targets. Our findings support
the hypothesis that siRNA can be effectively applied to
modulate nervous system function. The significant knock-
down of the target transcripts in both the DRG and the
spinal cord conforms with the established mechanism of
siRNA mediated gene silencing, and is consistent with the
uptake of siRNA seen in both the peripheral neurons (i.e.
DRG) and the central nervous system (i.e., spinal cord).
The low dose of siRNA further suggests that the efficacy of
RNAi depends critically on the efficient delivery of the
siRNA to the target tissues. Unlike antisense oligodeoxy-
nucleotides, siRNA may be delivered systemically [23].
Thus, chemical modifications that enhance systemic sta-
bility and facilitate siRNA transport across the BBB or the
uptake of siRNA by neurons would greatly advance the
potential of siRNA as therapeutic.
Methods
siRNA preparation
The siRNA sequence for the DOR (accession no. U00475,
the only gene sequence that is defined as delta opioid
receptor to date) was from nucleotides 364 to 384 relative
to the start codon. The sequences were as follows: sense 5'-
GGCUGUGCUCUCCAUUGACUU-3'; antisense 5'-
GUCAAUGGAGAGCACAGCCUU-3'. A scrambled
sequence was designed as a mismatch control: sense 5'-
GGCGUGUCUCUCUUACGACUU-3' and antisense 5'-
GUCGUAAGAGAGACACGCCUU-3'. BLAST search of the
nucleotide sequences in the GenBank database showed
no substantial homology with other genes. These 21-
nucleotide RNA oligonucleotides were synthesized indi-
vidually, deprotected and purified by RNase-free HPLC
(Midland Certified Reagent Company). siRNA and mis-
match RNA duplexes were formed in a concentration of
200 µM in annealing buffer as described [4] for 3 min at
90°C followed by 1 h at 37°C. The siRNA stocks were
aliquoted and stored at -80°C. For fluorescence labeling
of the siRNA, AlexaFluor 546 was conjugated at the 5' end
of the sense strand by solid phase synthesis and the tagged
siRNA was purified by HPLC (Qiagen) and resuspended
to a concentration of 200 µM in annealing buffer.
In vitro analysis of knock down of DOR in NG108-15 cells 
by the siRNA
NG108-15 Cells were cultured in 5% fetal calf serum/ 5%
newborn calf serum/ 45% Ham's F-12/ 45% DMEM/ 100
U mL-1 penicillin/ 100 µg mL-1 streptomycin (Invitrogen).
Cells were maintained in 75 cm2 flasks in a humidified
atmosphere with 95% air and 5% CO2. For experiments,
cells were seeded in 6-well plates at 3 × 105 cells/well 24
hr before the siRNA treatment. Cells were transfected with
2 µg of siRNA/i-Fect™ complexes in 1:4 ratio (w/v) per
well. Forty-eight hours after transfection, cells were har-
vested and total RNA was isolated. DOR transcripts were
detected by real-time RT-PCR (see below).
Quantitative RT-PCR
Total RNA was isolated from the lumbar dorsal spinal
cord, the L4 and L5 dorsal root ganglia using Aurum™
total RNA mini kit (Bio-Rad). Quantitative RT-PCR was
performed using the iCycler iQ Multicolor Real-Time PCR
Detection System with iScript cDNA Synthesis Kit and iQ
SYBR Green Supermix (Bio-Rad). All samples were run in
triplicate using an annealing temperature of 60°C. Prim-
ers for the amplification of DOR were: forward primer: 5'-
GTTCACCAGCATCTTCACG -3'(nuc. 396~414); reverse
primer: 5'-TGCATACCACTGCTCCATC -3'(nuc.
577~595). That for GAPDH were: forward primer: 5'-
ATCATCCCTGCATCCACTG-3'(nuc. 610~628); reverse
primer: 5'-GCCTGCTTCACCACCTTC -3'(nuc. 771–788).
All primers were synthesized by Midland Certified Rea-
gent Company, Inc. PCR efficiencies for DOR and
GAPDH were 97% and 98%, respectively, with correlation
coefficient of 0.999. Expression of DOR was normalized
to expression of GAPDH. The differences of DOR mRNA
expression between treatments were analyzed using the
Comparative CT Method (ABI Prism 7700 Sequence
Detection System User Bulletin #2, p11–15, 2001). The
threshold cycle (CT) is defined as the cycle at which the
amount of amplified PCR product from the target cDNA
reaches a fixed threshold. In each treatment, ∆CT = CT for
the target, DOR – CT for the endogenous reference,
GAPDH. ∆∆CT = ∆CT,treatment – ∆CT,control. The equation, 2-
∆∆CT, denotes the ratio of the level of DOR transcripts in
the treated group and that of the control group. This
number is converted to percent of control, where control
is set at 100.Page 6 of 8
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Male Sprague-Dawley rats, weighing between 200–220 g,
were used in these experiments. All the procedures used in
these experiments have been approved by the Institu-
tional Animal Care and Use Committee. Rats were
implanted with intrathecal (i.th.) catheters and allowed 7
days to recover from surgery prior to treatment. The rats
were divided into siRNA, mismatch RNA and vehicle
groups, with at least 6 rats per group. siRNA or mismatch
RNA complexes were prepared immediately prior to
administration by mixing the RNA solution (200 µM in
annealing buffer) with a transfection reagent, i-Fect™
(Neuromics), in a ratio of 1:4 (w:v) [24]. At this ratio, the
final concentration of RNA as an RNA/lipid complex was
2 µg in 10 µL. siRNA or mismatch RNA, or i-Fect™ alone
(defined as vehicle) in 10 µL was delivered to the lumbar
region of the spinal cord via the i.th. catheters. Injections
were given daily for 3 consecutive days. Nociceptive test-
ing and tissue harvest were carried out at 24 hr and 72 hr
after the last injection. The fluorescence tagged siRNA was
mixed with i-Fect™ and injected in the same manner as for
the untagged RNA, except that only one injection was
given and tissue harvested 24 hr later.
Nociceptive testing
Radiant heat paw withdrawal test using a movable infra-
red light source was employed as the nociceptive stimu-
lus. The experimenter who conducted the nociceptive
testing was blinded to the pretreatment of the experimen-
tal groups. The baseline latency for withdrawal of the left
hindpaw was recorded from the experimental animals 24
hr prior to RNA or vehicle administration. Twenty-four hr
following the last injection, the baseline latency was
recorded again. The rats then received either 30 µg of [D-
Ala2]deltorphin II (DELT) or 0.5 µg of [D-Ala2, N-Me-
Phe4, Gly-ol5]enkephalin (DAMGO) (Sigma)
intrathecally and the thermal latency were measured at
15-min interval over 60 min. A maximal cutoff latency of
33 s was used to prevent potential tissue injury. The %
antinociceptive effect of DELT or DAMGO was defined as:
[(treatment-baseline)/(cutoff-baseline)] × 100. The test-
ing was repeated at 72 hr after the last injection.
Saturation analysis of DOR by [3H]naltrindole
Crude membranes were prepared from the lumbar dorsal
spinal cords pooled from the rats in each treatment group,
resuspended in 50 mM Tris buffer, pH7.2, and the protein
content measured as previously described [18]. Saturation
analysis of [3H]naltrindole (20 Ci/mmol, PerkinElmer)
was carried out using 10 concentrations of [3H]naltrin-
dole (31.3 pM to 5 nM), done in triplicates, incubated
with 50 µg of membranes per assay tube in 0.5 mL buffer,
at a total volume of 1.0 mL, in a shaking water bath at
25°C for 3 hr. Non-specific binding of the radioligands
was defined by that in the presence of 10 µM naloxone.
The reactions were terminated by rapid filtration through
Whatman GF/B filters, followed by five washes with 4 mL
of ice-cold saline. The radioactivity was determined by liq-
uid scintillation counting. Data were analyzed by non-lin-
ear least squares regression analysis using GraphPad
Prism 4 (GraphPad software).
Immunohistochemical analysis of DOR and MOR and 
fluorescence imaging
Rats were deeply anesthetized with ketamine HCl/xyla-
zine (Sigma). The heart was exposed and transcardially
perfused with 10 mM sodium phosphate-buffered saline
(PBS, pH 7.4) until exudate ran clear, then switched to
10% buffered formalin for a further 15 min. Lumbar spi-
nal cords and the L4 and L5 DRG were isolated and post-
fixed in 10% buffered formalin for 24 hr and cryopro-
tected with 30% sucrose in 10 mM PBS. After pre-blocking
with 10% normal goat serum (Vector Laboratories), fron-
tal sections (20 µm) of the spinal cord were incubated
with either a rabbit anti-rat primary antibody for DOR
(1:2000) or a rabbit anti-rat primary antibody for MOR
(1:5000) at 4°C for 48 hr (both antibodies were from
Neuromics). Slides were rinsed with 2.5% normal goat
serum/PBS and then incubated with a secondary antibody
(AlexaFluor 594-conjugated goat anti-rabbit IgG (1:1000,
Molecular Probes) for 1 hour at room temperature. Slides
were again rinsed 3 times with the same buffer, dried, and
mounted for microscopy. Fluorescent imaging of the sam-
ples was carried out using Nikon E800 fluorescence
microscope equipped with 10×, 20× and 40×objective
lenses and standard filters for Y-2E/C TX RED, coupled to
a Hamamatsu C5810 color CCD camera (Hamamatsu
Photonic System) for digital image acquisition using
Adobe Photoshop software on a PC workstation. The
same system was used for the imaging of slide mounted
lumbar spinal cord and L4/L5 DRG (20 µm longitudinal
sections) from animals that have been injected with the
tagged siRNA, except that the filters for TRITC was used.
Statistical analysis
Significant differences among paw withdrawal latencies at
30-min time point after DELT or DAMGO injection were
determined by ANOVA followed by the post hoc least sig-
nificant differences test. Unpaired t-test was used for all
other between group comparisons.
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